Paclitaxel protein-bound particles for injectable suspension is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas.
Ganirelix acetate injection is used for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
Sucralfate Oral Suspension had a market value of $188.5 million, of which $157.9 million represents generic sales, for the 12 months ending December 2021, according to IQVIA.